Last reviewed · How we verify
pneumococcal conjugate 13 valent vaccine
Pneumococcal conjugate 13-valent vaccine stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.
Pneumococcal conjugate 13-valent vaccine stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and invasive disease in adults.
At a glance
| Generic name | pneumococcal conjugate 13 valent vaccine |
|---|---|
| Also known as | Prevenar13 |
| Sponsor | University of Siena |
| Drug class | Conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (13 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains capsular polysaccharides from 13 different serotypes of S. pneumoniae conjugated to diphtheria toxoid, which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease caused by these 13 serotypes. The antibodies produced help opsonize and facilitate clearance of pneumococcal bacteria.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal pneumonia and invasive disease in adults
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: